Altogether, we demonstrated that interrupting Zbtb16-Txnip-Trx2 signaling in atrium could decrease AF susceptibility via reducing ROS release and CaMKII activation in the setting of T2DM. The gene discussed is ZBTB16; the disease is type 2 diabetes mellitus.